Overview

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Status:
Not yet recruiting

Trial end date:
2023-03-10

Target enrollment:

Participant gender:

Summary

The study will assess the Pharmacokinetic (PK) and safety of BGF MDI [Budesonide/glycopyrronium/formoterol (BGF) metered dose inhaler (MDI)] formulated with 2 different propellants :Hydrofluoroolefin (HFO) and Hydrofluoroalkane (HFA) with oral activated charcoal in healthy subjects (male or female).

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Budesonide
Charcoal
Formoterol Fumarate